|Print Page Close Window|
“MC”-driven CIDeCARs proliferate, persist and eliminate tumors in preclinical studies
The studies evaluated in vivo tumor-killing abilities of two different CIDeCARs: CD19-targeted CIDeCAR cells (BPX-401) were evaluated in a Raji lymphoma model, and Her2-targeted CIDeCAR cells were evaluated in an SK-BR-3 breast cancer model.
“We believe the development of more potent CAR T cells will be critical
to success in bulky lymphomas and solid tumors,” commented
The poster, titled “MyD88/CD40-based costimulation to enhance survival and proliferation of chimeric antigen receptor (CAR)-modified T cells,” can be accessed on the Events and Presentations page of the Company’s website.
Bellicum is a clinical stage biopharmaceutical company focused on discovering and developing novel cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company is using its proprietary Chemical Induction of Dimerization, or CID, technology platform to engineer and control components of the immune system in real time. Bellicum is developing next-generation product candidates in some of the most important areas of cellular immunotherapy, including hematopoietic stem cell transplantation, or HSCT, CAR-T and TCR cell therapy, and dendritic cell vaccines. More information can be found at www.bellicum.com.
*CaspaCIDe® is a trademark registered with the U.S. Patent and Trademark Office.
CIDeCAR™ is a trademarks of
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Bellicum may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should" or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: the timing of our clinical trials and of
our research and development activities relating to BPX -401, CaspaCIDe
and CIDeCAR and our expectations regarding our other programs. Various
factors may cause differences between Bellicum’s expectations and actual
results as discussed in greater detail in Bellicum’s filings with the